Welcome to our dedicated page for Anaptysbio SEC filings (Ticker: ANAB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
AnaptysBio, Inc. filings document the company’s transition to a royalty management business and its Nasdaq-listed common stock under the symbol ANAB. Recent Form 8-K and 8-K/A filings cover the completed separation of First Tracks Biotherapeutics, related separation and transition services agreements, pro forma financial information, and material-event reporting tied to the new corporate structure.
The filing record also includes disclosures on operating and financial results, Regulation FD materials, stock repurchase authorizations, governance matters, and contract litigation involving the Jemperli Collaboration and Exclusive License Agreement. These documents frame AnaptysBio’s capital structure, collaboration rights, royalty-related business focus, and public-company reporting obligations.
AnaptysBio (symbol ANAB) disclosed a planned insider sale of common stock under Rule 144. The notice covers 2,515 shares of common stock to be sold through Morgan Stanley Smith Barney LLC on NASDAQ, with an aggregate market value of 113,703.15. These shares come from restricted stock units acquired from the issuer on 01/08/2026, with cash as the form of payment.
The filing also lists recent sales by Dennis Mulroy over the prior three months. These include 1,908 shares sold on 01/07/2026 for 83,780.28, 3,363 shares on 01/05/2026 for 1,511,166.85, 10,000 shares on 12/22/2025 for 500,000, and 15,725 shares on 12/16/2025 for 705,333.1. The Rule 144 representation confirms the seller states they are not aware of undisclosed material adverse information about the issuer.
AnaptysBio chief legal officer Eric Loumeau reported RSU vesting and a related tax sale of shares. On January 7, 2026, 5,888 restricted stock units were converted into the same number of shares of AnaptysBio common stock at an exercise price of $0, reflecting that each RSU settles into one share for no cash consideration. After this transaction, Loumeau held 15,045 shares of common stock directly.
On January 8, 2026, he sold 2,210 shares of common stock at a price of $44.71 per share. The filing explains that this sale was executed solely to cover tax withholding obligations arising from the RSU vesting through a “sell to cover” transaction and was not a discretionary sale. Following the sale, Loumeau directly owned 12,835 shares of common stock and 17,662 RSUs that continue to vest in 25% annual increments starting January 7, 2026, contingent on continued service.
A holder of the issuer’s common stock has filed a Rule 144 notice to sell 2,210 shares through Morgan Stanley Smith Barney, with an aggregate market value of $99,914.10. The filing lists 27,688,470 shares of common stock outstanding and targets an approximate sale date of 01/08/2026 on the NASDAQ market.
The 2,210 shares were acquired on 01/08/2026 as restricted stock units from the issuer, paid for in cash. Over the prior three months, the seller, identified as Eric J. Loumeau, reported multiple sales of the issuer’s common stock, including several transactions of 10,000 shares in December 2025 and additional sales in January 2026, each with disclosed gross proceeds.
AnaptysBio President and CEO Daniel Faga, who is also a director, reported the vesting of 26,838 restricted stock units (RSUs) on January 7, 2026. Each RSU converts into one share of common stock for no cash cost, increasing his directly held common shares to 493,625 and leaving 80,512 RSUs outstanding.
On January 8, 2026, Faga reported selling 14,281 shares of common stock at $44.71 per share. According to the disclosure, this sale was made solely to cover tax withholding obligations arising from the RSU vesting through a “sell to cover” transaction, and was not a discretionary trade.
Daniel Faga filed a Rule 144 notice to sell 14,281 shares of common stock through Morgan Stanley Smith Barney LLC on or about 01/08/2026, with an aggregate market value of 645,644.01 and 27,688,470 shares outstanding.
The shares to be sold were acquired on 01/08/2026 as restricted stock units from the issuer and paid for in cash. The filing also reports earlier sales over the prior three months, including 9,202 shares sold on 01/07/2026 for gross proceeds of 404,059.82 and 15,309 shares sold on 01/05/2026 for gross proceeds of 688,139.55.
AnaptysBio, Inc. filed a current report to highlight preliminary year-end liquidity it plans to share at the 2026 J.P. Morgan Healthcare Conference. The company expects to report that it had cash, cash equivalents and investments of approximately $310 million as of December 31, 2025.
The figure is described as preliminary and unaudited, and may change once normal year-end closing procedures and the independent audit are completed. AnaptysBio notes that its audited financial statements for the year ended December 31, 2025 are not yet available and that additional information will be needed for a full picture of its financial position and results. The conference presentation containing these details is being furnished as an exhibit and is explicitly not deemed filed for liability purposes under the securities laws.
AnaptysBio, Inc.’s chief legal officer Eric J. Loumeau reported equity award activity and related share sales. On January 6, 2026, 5,545 restricted stock units (RSUs) were settled into the same number of common shares for no cash consideration, and he received a new grant of 17,100 RSUs plus a stock option for 23,200 shares with a $43.91 exercise price.
On January 7, 2026, he reported several sales of common stock at weighted average prices around the mid‑$40s per share, including blocks such as 2,017 shares at $45.11 and 5,281 shares at $45.3839. Footnotes state that some shares were sold to cover tax withholding on RSU vesting and that the transactions were executed under a Rule 10b5‑1 trading plan. Following these transactions, he directly held 9,157 common shares.
ANAB filed a Form 144 notice for a planned insider stock sale. The filing shows a planned sale of 2,017 shares of common stock through Morgan Stanley Smith Barney on the NASDAQ, with an aggregate market value of $88,566.47. The shares relate to restricted stock units acquired from the issuer on January 7, 2026 and paid for in cash. The filing lists 27,688,470 shares of the issuer’s common stock outstanding.
The notice also reports prior transactions by Eric J. Loumeau over the past three months, including sales such as 12,500 shares on December 16, 2025 for $560,800.25 and 10,000 shares on December 17, 2025 for $460,000. By signing, the seller represents that they are not aware of undisclosed material adverse information about the issuer’s current or prospective operations.
AnaptysBio, Inc. Chief Medical Officer Paul F. Lizzul reported multiple equity transactions. On January 6, 2026, 6,145 restricted stock units (RSUs) converted into the same number of common shares for no cash cost, and his common stock holdings became 39,448 shares. That day he also received 21,400 new RSUs and a stock option for 29,000 shares.
The new RSUs vest 25% per year starting January 6, 2027, while the option vests 25% on January 6, 2027 and then monthly in equal installments, all contingent on continued service. On January 7, 2026, he sold 2,235 common shares at $45.11 solely to cover tax withholding from the RSU vesting, leaving 37,213 common shares owned directly.
AnaptysBio shareholder Paul F. Lizzul filed a Rule 144 notice to sell 2,235 shares of the company’s common stock. The planned sale is to be executed through Morgan Stanley Smith Barney LLC, with an aggregate market value of 98138.85, and an approximate sale date of 01/07/2026 on the NASDAQ.
The shares were acquired as restricted stock units from the issuer and paid for in cash on 01/07/2026. The filing notes that 27,688,470 common shares were outstanding. Over the prior three months, Lizzul sold 4,219 common shares on 01/05/2026 for gross proceeds of 189644.05 and 1,500 common shares on 12/22/2025 for gross proceeds of 75000.